HC Wainwright Has Negative View of Opus Genetics Q1 Earnings

Opus Genetics, Inc. (NASDAQ:IRD) – Equities research analysts at HC Wainwright lowered their Q1 2026 earnings per share estimates for Opus Genetics in a research note issued to investors on Wednesday, March 11th. HC Wainwright analyst M. Caufield now forecasts that the company will earn ($0.16) per share for the quarter, down from their prior estimate of ($0.09). The consensus estimate for Opus Genetics’ current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for Opus Genetics’ Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.64) EPS, FY2027 earnings at ($0.48) EPS, FY2028 earnings at ($0.20) EPS, FY2029 earnings at ($0.01) EPS and FY2030 earnings at $0.21 EPS.

Several other analysts also recently commented on the stock. Lifesci Capital raised shares of Opus Genetics to a “strong-buy” rating in a report on Thursday, February 12th. BTIG Research raised their target price on shares of Opus Genetics from $7.00 to $12.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. B. Riley Financial assumed coverage on shares of Opus Genetics in a research report on Wednesday, December 10th. They set a “buy” rating and a $9.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Opus Genetics in a report on Thursday, January 22nd. Finally, Brookline Capital Acquisition raised Opus Genetics to a “strong-buy” rating in a research report on Monday, December 1st. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $9.25.

Opus Genetics Price Performance

Shares of NASDAQ:IRD opened at $4.84 on Friday. Opus Genetics has a twelve month low of $0.65 and a twelve month high of $5.30. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt-to-equity ratio of 0.18. The company has a market cap of $333.77 million, a PE ratio of -5.90 and a beta of 0.45. The company’s 50 day moving average is $3.13 and its 200 day moving average is $2.30.

Institutional Investors Weigh In On Opus Genetics

Several hedge funds have recently modified their holdings of IRD. Comerica Bank acquired a new stake in shares of Opus Genetics during the 1st quarter valued at about $29,000. Royal Bank of Canada purchased a new position in shares of Opus Genetics in the 1st quarter valued at about $299,000. BIOS Capital Management LP raised its holdings in Opus Genetics by 270.1% in the 2nd quarter. BIOS Capital Management LP now owns 3,683,429 shares of the company’s stock worth $3,462,000 after purchasing an additional 2,688,180 shares during the period. Voss Capital LP raised its holdings in Opus Genetics by 260.8% in the 2nd quarter. Voss Capital LP now owns 541,159 shares of the company’s stock worth $510,000 after purchasing an additional 391,159 shares during the period. Finally, Nantahala Capital Management LLC boosted its position in Opus Genetics by 6.0% during the second quarter. Nantahala Capital Management LLC now owns 3,345,923 shares of the company’s stock worth $3,152,000 after purchasing an additional 188,028 shares in the last quarter. 14.97% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Cam Gallagher purchased 83,000 shares of the company’s stock in a transaction that occurred on Monday, December 29th. The shares were bought at an average price of $1.97 per share, for a total transaction of $163,510.00. Following the completion of the transaction, the director owned 83,000 shares in the company, valued at $163,510. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 6.60% of the company’s stock.

Trending Headlines about Opus Genetics

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: BTIG raised its price target to $12 and maintained a Buy rating, signaling renewed upward investor expectations. BTIG price target raise
• Positive Sentiment: Chardan raised its price target to $11 (Buy) and Wedbush raised its target to $10 (Outperform), both implying double‑digit upside vs. the current trading level. Chardan/Wedbush coverage (Benzinga) Wedbush (TickerReport)
• Positive Sentiment: Nyxol Phase‑3 trial activity is approaching a data readout, creating a near‑term clinical catalyst that could move the stock if results are favorable. Nyxol presbyopia trial update Viatris Nyxol Phase 3 note
• Neutral Sentiment: H.C. Wainwright publicly reiterated a Buy rating even as it adjusted forecasts, which supports investor conviction but highlights divergent analyst views. H.C. Wainwright buy rating
• Negative Sentiment: HC Wainwright cut multiple near‑term EPS estimates sharply (Q1–Q4 2026 now modeled at about ($0.16) per quarter and FY2026 to ($0.64) from prior forecasts), pushing out the timeline to profitability for several years — a key reason for today’s downward pressure.
• Negative Sentiment: Lifesci Capital also trimmed Q1/Q2 and FY2026 EPS estimates (while retaining a “Strong‑Buy”), lowering FY2026 expectations and reinforcing the weaker near‑term earnings outlook.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.